Description: Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Home Page: www.scinai.com
Jerusalem BioPark
Jerusalem,
Israel
Phone:
972 8 930 2529
Officers
| Name | Title |
|---|---|
| Mr. Amir Reichman M.B.A., M.Sc. | CEO & Director |
| Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA | Chief Financial Officer |
| Mr. Elad Mark B.Sc., Eng., M.B.A. | Chief Operating Officer |
| Dr. Dalit Weinstein Fischer Ph.D. | Chief Technology Officer |
| Dr. Tamar Ben-Yedidia Ph.D. | Chief Scientist |
| Liat Halpert | Head of Business Development & Sales |
| Merav Kamensky | Head of Quality Control |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Information Technology |
|---|---|
| GIC Group: | Semiconductors & Semiconductor Equipment |
| GIC Industry: | Semiconductors & Semiconductor Equipment |
| GIC Sub-Industry: | Semiconductor Materials & Equipment |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 1.4016 |
| Price-to-Book MRQ: | 0.6569 |
| Price-to-Sales TTM: | 10.272 |
| IPO Date: | 2015-05-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 31 |